Download Nasser Samadi, PhD

Curriculum vitae
Nasser Samadi, PhD
Associate Professor
Department of Biochemistry and Laboratory Medicine
Faculty of Medicine
Tabriz University of Medical Sciences
Gholgasht Ave, Tabriz University For Medical Sciences, Faculty of Medicine
Tabriz, Iran
Phones: (0413) 3355789 (office)
E-MAIL: [email protected]
_________________________________________________________________________
EDUCATION
University of Alberta, Edmonton, Canada
Post Doctoral Fellowship, Medical Biotechnology, Department of Biochemistry (Oct `
2009- June 2011)
Supervisor: Dr. David N Brindley
Research area: Role of Bioactive Lipid Molecules in Chemoresistance in Cancer
Philosophy Doctorate (PhD) in Clinical Biochemistry (May 2004-Sep 2009)
Thesis: Autotaxin, Lysophosphatidate and Taxol Resistance
Supervisor: Dr. Fiona J Bamforth
Advisors: Dr. David N Brindley, Dr. George S Cembrowski, Dr. Luis Schang, Dr. Ing
Swie Goping
Courses taken in the University of Alberta: Data analysis (3 credits), Human disease (3
credits), Select topics in protein structures/functions (3 credits), Direct reading in clinical
biochemistry (3 credits)
Tabriz University of Medical Sciences, Tabriz, Iran
Doctorate Degree in Laboratory Medicine (1991-1996)
Thesis: Evaluation of NBT (Phagocytosis) in Patients with Hemodialysis and Kidney
Transplantation and Its Comparison with Control Groups (Patients with Chronic Renal Disease
Without Dialysis and Healthy Indivituals).
Supervisor: Dr. Hassan Organi
Advisors: Dr. Badr Rahnema, Dr. Mahin Mozaffari, Dr. Zahra Rajaee
Selected courses taken in the University of Alberta:
Physiology (9 credits), Anatomy (5 credits), Histology (4 credits), Pathology (12 credits),
Analytical chemistry (3 credits), Statistics (6 credits), Genetics (2 credits), Biology and biophysics
(6 credits), Medical biochemistry (18 credits), Hematology and transfusion medicine (14 credits),
Bacteriology and virology (14 credits), Toxicology and forensic medicine (4 credits), Immunology
and serology (11 credits), Parasitology and mycology (15 credits), Physiopathology (16 credits
including Digestive system, Heart and Blood circulation, Endocrine and metabolism, pulmonary
diseases, Renal diseases, infectious diseases, Hematophatology and Rheumatic diseases). Rotation
in medical laboratories (14 months).
Bachelor of Science Degree in Laboratory Medicine (1987-1989).
1
RESEARCH EXPERIENCE













Studies on cancer stem cell isolation and characterization
Studied on different drug delivery techniques based on medical nanotechnology and
biotechnology approaches
Studied on the role of bioactive lipid molecules in chemoresistance in different cancer
cells.
Investigated the development of implanted breast cancer cells and their metastasis in
autotaxin transgenic mice
Studied on autotaxin, lysophosphatidate receptors and survivin as diagnostic and
prognostic markers for cancer patients
Investigated the role of autotaxin in resistance against apoptosis and tumor progression.
Studied the impact of lysophosphatidate and lysophosphatidylcholine in tumor resistance
against chemotherapy.
Investigated several signaling pathways related to tumor development and
chemoresistance
Developed and validated of a method for quantitative analysis of different markers for
metabolic diseases in newborn by Tandem Mass Spectrometry
Studied statistical data analysis and on-line data acquisition for the role of thyroid
hormones and liver enzymes in overweight and obesity in different ethnic groups
Studied the application of cardiac markers for evaluation of patients after open heart
surgery
Investigated the effectiveness of phagocytosis in hemodialyzed and kidney-transplanted
patients.
Experienced in tissue culture, cellular proliferation and apoptosis assays, multi-color
flow cytometry, ELISA (enzyme-linked immunosorbant assay), RIA (radio immune
assay), RT-PCR, Western blot analysis, radioisotope handling, animal experimentation,
fluorometry, immunocytochemistry, confocal and fluorescence microscopy and Tandem
mass spectrometry
.
TEACHING AND EMPLPYMENT HISTORY
Dean of the Faculty of Advanced Biomedical Sceinces, Tabriz University for Medical
Sciences
Head of the department, Department of Biochemistry and Laboratory Medicine, Tabriz
University of Medical Sciences
Head of the department, Department of Genetics, Faculty of Medicine, Tabriz University of
Medical Sciences
Associate Professor, Departments of Medical Biotechnology, Pharmaceutical Biotechnology
and Medical Biochemistry.
Postdoctoral Fellow, Department of Biochemistry, University of Alberta, Edmonton, Alberta,
Canada (2009-continued).
Director of Clinical Laboratory, Madani Cardiovascular Research, Treatment, and Trading
Centre, Tabriz-Iran (1999-2003).
Instructor for Biochemistry and Hematology, Tabriz University for Medical Sciences, Tabriz,
Iran (1997-2003).
Researcher and Clinical Laboratory Expert, Reference Clinical Laboratory of Tabriz, Iran,
(1996-1999).
2
PRESENTATIONS
















Evaluation of Nrf2 expression level by IHC and real time PCR in colorectal cancer.13th
International Congress of Immunology and Allergy of Iran, 12523P, 26-29 April, 2016,
Tabriz, Iran
Arsenic trioxide increases paclitaxel-induced apoptosis in resistant breast cancer cells. 14th
St.Gallen International Breast Cancer ConferenceVienna, Austria, 18–21 March 2015 The
Breast 24S1 (2015). S26–S86.
Expression of Six1 gene involved in apoptosis in MCF-7 cells sensitive and resistant to
paclitaxel. 14th St.Gallen International Breast Cancer ConferenceVienna, Austria, 18–21
March 2015 The Breast 24S1 (2015). S26–S86.
Nasser Samadi., Mehdi Sabzichi, Quercetin enhances sensitivity of MDA-MB231cell to
doxorubicin by negative regulation of Nrf2pathway. J Cancer Sci Ther August 03-05, 2015
Birmingham, UK.
Armat M., Oghabi Bakhshaiesh T., Hejazi M.S., Samadi N. Expression of Six1 gene
involved in apoptosis in MCF-7 cells sensitive and resistant to paclitaxel. The Breast 24S1
(2015) S26–S86. Italy.
Oghabi Bakhshaiesh T., Armat M., Sharifi S., Hejazi M.S., Arsenic trioxide increases
paclitaxel-induced apoptosis in resistant breast cancer cells. The Breast 24S1 (2015) S26–
S86. Italy.
Samadi N, Ramezani F, Sabzichi M. 72 Nrf2 as a molecular target in overwhelming
chemoresistance in breast cancer therapy. European Journal of Cancer. 2014; 50:28.
Samadi N, Mohseni M, Ghanbari P, Nazemeyeh H, Tondar M, Ghanbari P,
Tabasinezhad M. Role of P-glycoprotein in chemo-resistance of lung cancer stem cell line.
23th IMSSC, 2012, Istanbul.
Samadi N, Ghanbari P, , Rashidi MR, Saei AA, Tabasinezhad M. Role of survivin in
chemoresistance of breast cancer stem line. 23th IMSSC, 2012, Istanbul.
Autotaxin and lysophosphatidate produce chemoresistance by releasing breast cancer cells
from Taxol-induced mitotic arrest, International Conference of Chemistry and Physics of
Lipids, Bilbao, Spain, 2010.
Lysophosphatidate releases breast cancer cells from Taxol-induced G2/M arrest and cell
death, FASEB summer research conferences, Carefree, Arizona, USA. June 2009.
Lysophosphatidate releases MCF-7 cells from Taxol-induced G2/M arrest. University of
Macgregor Lecture and Research day, Alberta, Canada. Oct.2008.
Lysophosphatidic acid protects MCF-7 breast cancer cells against Taxol-induced
apoptosis. Macgregor Lecture and Research day, University of Alberta, Canada. Oct.2007.
Data Mining of serum vitamin measurements in 1999-2004 NHANES demonstrates lower
water soluble vitamin levels but higher fat soluble vitamin levels in obese Americans,
American Association of Clinical Chemistry (AACC) annual Meeting, San Diego, CA,
USA. July 2007.
Regulation of autotaxin in breast cancer cells. Oral presentation. Macgregor Lecture and
Research day, University of Alberta, Canada. Oct.2006.
Impact of Overweight on Liver Enzyme Activity in Older Individuals of NHANES
population (1999-2002). The Canadian Institutes of Health Research Poster Competition.
University of Manitoba, Winnipeg, Canada, June 2006.
3

Waist Circumference is Correlated to TSH in Apparently Healthy Obese Individuals.
American Association of Clinical Chemistry (AACC) annual Meeting, Chicago IL, USA
July 2006.
Pediatric Hematologic Reference Intervals, Laboratory Medicine and Pathology Round
Presentation, University of Alberta, Canada, March 2006.
Cardiac Case Presentation, Bell Lecture, University of Alberta, June 2005.
Metabolic Syndrome, Laboratory Medicine and Pathology Round Presentation, University
of Alberta, Canada, Apr.2005.
Newborn Screening for Inborn Error of Metabolism by Tandem Mass Spectrometry.
Oral presentation. Macgregor Lecture and Research day, University of Alberta, Canada.
Sep 2004.
The role of Clinical Laboratory for Prevention of Nosocomial Infections. Nocosomial
Infection and Surgery Meeting, University of Tabriz, Iran, June 2002.
Evaluation of Phagosytosis in Hemodialysis Patients by Nitro Blue Tetrazolium Test.
International Conference of Nephrology, Tehran, Iran, Apr. 1996.






HONOURS and AWARDS
1. The Bell McLeod Educational Fund from Department of Laboratory Medicine and
Pathology, University of Alberta, 2007-2008
2. Travel grant from department of laboratory medicine and pathology, University of Alberta
for attending in the AACC annual meeting, San Diego, CA, July 2007.
3. Travel grant from department of laboratory medicine and pathology, University of Alberta
for attending in the AACC annual meeting, Chicago, IL, July 2006.
4. Travel grant from department of laboratory medicine and pathology, University of Alberta
for attending in CIHR poster competition, Winnipeg, June 2006.
5. Travel grant from department of laboratory medicine and pathology, University of Alberta
for attending in AACC annual meeting, Orlando, FL, July 2005.
6. Scholarship for four years to do PhD in the field of clinical biochemistry from Iranian
Ministry of Health for top three students in Clinical Biochemistry, 2003.
7. Certificate of appreciation from WHO-INTER HEART, 2002.
8. Certificate of appreciation from Shahid Madani Cardiovascular Research, Treatment &
Trading Center, Tabriz, Iran, 2000.
PROFESSIONAL SOCIETY MEMBERSHIPS



The Canadian Society for Clinical Chemistry
The American Association for Clinical Chemistry
Iranian Society of Physicians
PEER REVIEWED PAPERS

Dolatkhah H, Movahedian A, Somi MH, Aghaei M, Samadi N, Mirza-Aghazade A,
Esfahani A. Effect of PUFAs oral administration on the amount of Apoptotic Caspases
4
Enzymes in gastric cancer patients undergoing chemotherapy. Anticancer Agents Med
Chem. 2016 May 20. [Epub ahead of print].

Sabzichi M, Samadi N, Mohammadian J, Hamishehkar H, Akbarzadeh M, Molavi O.
Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in
breast cancer treatment. Colloids Surf B Biointerfaces. 2016 Apr 22;145:64-71. doi:
10.1016/j.colsurfb.2016.04.042. [Epub ahead of print].

Mohseni M, Samadi N, Ghanbari P, Yousefi B, Tabasinezhad M, Sharifi S, Nazemiyeh H.
Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemoresistance. Iran J Basic Med Sci. 2016 Mar;19(3):300-9.

Armat M, Ramezani F, Molavi O, Sabzichi M, Samadi N, Six family of homeobox genes
and related mechanisms in tumorigenesis protocols. Tumori. 2016 Apr 5:0. doi:
10.5301/tj.5000495. [Epub ahead of print].

Yousefi B, Zarghami N, Samadi N, Majidinia M. Peroxisome Proliferator-activated
Receptors and their ligands in cancer drug resistance: opportunity or challenge. Anticancer
Agents Med Chem. 2016 Feb 3. [Epub ahead of print].

Yousefi B, Samadi N, Baradaran B, Shafiei-Irannejad V, Zarghami N. Peroxisome
proliferator-activated receptor ligands and their role in chronic myeloid leukemia:
Therapeutic strategies. Chem Biol Drug Des. 2016 Feb 3. doi: 10.1111/cbdd.12737. [Epub
ahead of print].

Zununi Vahed S, Samadi N, Mostafidi E, Ardalan MR, Omidi Y. Genetics and
Epigenetics of Chronic Allograft Dysfunction in Kidney Transplants. Iran J Kidney Dis.
2016 Jan;10(1):1-9.

Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N. Co-delivery with nanoquercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep.
2016 Feb; 43(2):99-105.

Armat M1, Oghabi Bakhshaiesh T, Sabzichi M, Shanehbandi D, Sharifi S, Molavi O,
Mohammadian J, Saeid Hejazi M, Samadi N. The role of Six1 signaling in paclitaxeldependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci. 2016 Jan 1. doi:
10.17305/bjbms.2016.674. [Epub ahead of print].

Veisi K, Farajnia S, Zarghami N, Khoram Khorshid HR, Samadi N, Ahdi Khosroshahi S,
Zarei Jaliani H. Chaperone-Assisted Soluble Expression of a Humanized Anti-EGFR ScFv
Antibody in E. coli. Adv Pharm Bull. 2015 Dec; 5(Suppl 1):621-7. doi:
10.15171/apb.2015.084. Epub 2015.
5

Yousefi B, Samadi N, Baradaran B, Rameshknia V, Shafiei-Irannejad V, Majidinia M,
Targhaze N, Zarghami N. Differential effects of peroxisome proliferator-activated receptor
agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Cell
Mol Biol. 2015 Dec 30; 61(8):118-22.

Tabasinezhad M1, Ghaedi H2, Qanbari P3, Mohseni M3, Sabzichi M3, Samadi N .
Sphingosine 1-phosphate interacts with Survivin pathway to enhance tumorigenesis in
cancer cells. Iran J Basic Med Sci. 2015 Aug;18(8):813-21.

Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R. Silibinin suppresses NPM-ALK,
potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic
large cell lymphoma. Leuk Lymphoma. 2015 Jul 1:1-27. [Epub ahead of print]

Bakhshaiesh TO, Armat M, Shanehbandi D, Sharifi S, Baradaran B, Hejazi MS, Samadi
N. Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Asian Pac J Cancer Prev. 2015; 16(13):5191-5197.

Zununi Vahed, Ardalan Mohammadreza, , Samadi N, Omidi Y. Pharmacogenetics and
drug-induced nephrotoxicity in renal transplant recipients. BioImpacts, 2015, 5(1), 45-54.

Mohammadi S, Shahbazi Mojarrad J, Zakeri-Milani3 P, Shirani A, Farkhani S, Samadi
N, Valizadeh H. Synthesis and In Vitro Evaluation of Amphiphilic Peptides and Their
Nanostructured Conjugates. Adv Pharm Bull, 2015, 5(1), 41-49.

PirouzpanahM, Sabzichi M, PirouzpanahS, Chavoshi H, Samadi N. Silibilin-Induces
Apoptosis in Breast Cancer Cells by Modulating p53, p21, Bak and Bcl-xl Pathways.
Asian Pacific Journal of Cancer Prevention, Vol 16, 2015. 2087-92.

Zarouni M, Salehi R, Akbarzadeh A, Samadi N, Davaran S, Ramezani F, et al.
Biocompatible Polymer Coated Paramagnetic Nanoparticles for Doxorubicin Delivery:
Synthesis and Anticancer Effects against Human Breast Cancer Cells. International Journal
of Polymeric Materials and Polymeric Biomaterials. 2015; 64:718-22.

Kamal Veisi K, Safar Farajnia S, Zarghami N, KhoramKhorshi H, Samadi N, Ahdi
Khosroshahi S, Zarei Jalian H. Chaperone-Assisted Soluble Expression of a Humanized
Anti-EGFR ScFv Antibody in E. coli. Adv Pharm Bull, 2015, 5(Suppl 1), x-x

Yousefi B, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression
and invasiveness of cancer. DNA repair. 2014;22:24-9.

Shirani A, Mojarrad JS, Farkhani SM, Zakeri-Milani P, Samadi N, Sharifi S, et al. The
Relation between Thermodynamic and Structural Properties and Cellular Uptake of
Peptides Containing Tryptophan and Arginine. 2015.
6

Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin Changes Bax/Bcl-xL Ratio,
Caspase-8 and 9 in Breast Cancer Cells. 2015.

Dehghani S, Maleksabet A, Sharifi S, Izadi M, Nazemiyeh H, Samadi N. The effect of
dichloromethane extract from Humulus lupulus L. on two human breast cancer cell lines.
International Journal of Biosciences (IJB). 2015;6(1):171-8.

Samadi N, Ghanbari P, Mohseni M, Tabasinezhad M, Sharifi S, Nazemieh H, Rashidi
MR. Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in
cancer cells. J Cancer Res Ther. 2014 Jul-Sep;10(3):715-21.

Ghanbari P1, Mohseni M, Tabasinezhad M, Yousefi B, Saei AA, Sharifi S, Rashidi MR,
Samadi N. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel
and vinblastine. Appl Biochem Biotechnol. 2014 Sep;174(2):667-81

Sharifi S, Barar J, Hejazi MS, Samadi N. Roles of the bcl-2/bax ratio, caspase-8 and 9 in
resistance of breast cancer cells to Paclitaxel. Asian Pacific Journal of Cancer Prevention.
2014;15(20):8617-22.

Salehi R, Aghazadeh M, Rashidi M, Samadi N, Salehi S, Davaran S, et al. Bioengineering
of Dental Pulp Stem Cells in a Microporous PNIPAAm-PLGA Scaffold. International
Journal of Polymeric Materials and Polymeric Biomaterials. 2014;63(15):767-76.

Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M,
Samadi N, et al. Luteolin-loaded Phytosomes Sensitize Human Breast Carcinoma MDAMB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling. Asian Pac J
Cancer Prev. 2014;15:5311-6.

Yousefi B, Faghfoori Z, Samadi N, Karami H, Ahmadi Y, Badalzadeh R, et al. The effects
of Ramadan fasting on endothelial function in patients with cardiovascular diseases.
European journal of clinical nutrition. 2014;68(7):835-9.

P Ghanbari, N Samadi, M Tabasinezhad, M Mohseni, B Yousefi, MR Rashidi. Adjuvant
therapy improves the chemotherapeutic effect of docetaxel and vinblastine in breast cancer
cells. European Journal of Cancer 2014; 50: S209

Pourhassan A, Samadi N, Nourazarian A, Nourazarian SM. The Study of Chronic
Hepatitis C Patients and the Prevalence of Viremia among Their First-Degree Relatives by
the Tabriz University of Medical Sciences. Advances in Environmental Biology.
2014;8(16).

Ghorbanihaghjo A, Argani H, Samadi N, Valizadeh S, Halajzadeh J, Yousefi B, et al.
Relationship Between Vitamin D Receptor Gene FokI and ApaI Polymorphisms and
7
Serum Levels of Fetuin-A, Vitamin D, and Parathyroid Hormone in Patients on
Hemodialysis. Iranian journal of kidney diseases. 2014;8(5):394-400.

Alidadiyani N, Salehi R, Ghaderi S, Samadi N, Davaran S. Synergistic antiproliferative
effects of methotrexate-loaded smart silica nanocomposites in MDA-MB-231 breast
cancer cells. Artificial cells, nanomedicine, and biotechnology. 2014(0):1-7.

Samadi N, Ghojazade M, Yaghoubi AR. Association between inflammatory factor, lipid
peroxidation and total-antioxidant in non-diabetic patients of coronary artery disease.
Journal of Analytical Research in Clinical Medicine. 2013;2(1).

Tabasinezhad M, Samadi N, Ghanbari P, Mohseni M, Saei AA, Sharifi S, Saeedi N,
Pourhassan A. Sphingosin 1-phosphate contributes in tumor progression. J Cancer Res
Ther. 2013 Oct-Dec;9(4):556-63.

Mehdizadeh Aghdam E, Mahmoudi Azar L, Barzegari A, Karimi F, Mesbahfar M,
Samadi N, Hejazi MS, Effect of periplasmic expression of recombinant mouse
interleukin-4 on hydrogen peroxide concentration and catalase activity in Escherichia coli,
Gene 2012, 455-60

Rahnema B, Rajaii M, Argani H, Samadi N. Effect of Urea and Creatinin on Nitro Blue
Tetrazolium Test in Hemodialysed Pateints and Transplanted Cases. Medical Journal of
Tabriz University, Iran, 2001; 152-161

Rahbani M, Parvizi R, Samadi N. Determination of the Amount of Aflatoxin in
Pasteurized Milk in Tabriz City. Medical Journal of Tabriz University, Iran, 2002; 98-105.

Rahbani M, Samadi N. Evaluation of Microalbuminuria in Patients Suffering From
Atherosclerosis. Medical Journal of Tabriz University, Iran, 2003; 58-64.

Samadi N, Cembrowski GS, Chan J. Effect of waist circumference on reference intervals
of liver-related enzyme tests in apparently healthy adult Mexican Americans, black and
white Americans. Clin Biochem. 2007; 40(3-4):206-12.

Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition
of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of
human breast cancer and melanoma cells. Mol Carcinog. 2009; 48(9):801-9.

Samadi N, Bekele, R., Schang, L., Goping, I. and Brindley, D. Lysophosphatidate Induces
Chemo-resistance by Releasing Breast Cancer Cells from Taxol induced mitotic arrest.
PLoS One. 2011; 6(5):e20608. Epub 2011 May 27
8

Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M and Brindley D N,
Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases
with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. 2010
Biochemie, Biochimie. 2011 Jan; 93(1):61-70.

Samadi, N, Bekele, R., Schang, L., Goping, I. and Brindley, D. (Submitted)
Lysophosphatidate prevents Taxol-induced killing of breast cancer cells by increasing
survivin expression and release from G2/M arrest.

Samadi N, Gaetano C, Goping IS, Brindley DN. Autotaxin protects MCF-7 breast cancer
and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 2009 19;
28(7):1028-39.
REFERENCES
Dr. Fiona J Bamforth, Professor and Chair
Department of Laboratory Medicine and pathology
University of Alberta, Edmonton
Tel: (780) 407-7379 or (780) 407-8820
E-mail: [email protected]
Dr. George S Cembrowski, Associate Professor and Director
Division of Medical Biochemistry, Department of Laboratory Medicine and pathology
University of Alberta, Edmonton
Alberta, Canada
Tel: (780) 407-3185
E-mail: [email protected]
Dr. David N Brindley, Professor
Department of Biochemistry
University of Alberta, Edmonton
Alberta, Canada
Tel: (780) 492-2078
E-mail: [email protected]
Dr. Raymond Lai, Professor
University of Alberta
Team Leader
Lymphoma Diagnostic Service and Molecular Pathology
Cross Cancer Institute
Edmonton, Alberta, Canada
Tel: (780) 432-8338
Email: [email protected]
9
Dr. Donald F. LeGatt, Professor
Department of Laboratory Medicine & Pathology
University of Alberta Hospitals
Edmonton, Alberta, Canada
Tel: (780) 407-8444
[email protected]
Dr. Ing Swie Goping, Assistant Professor
Department of Biochemistry
University of Alberta, Edmonton
Alberta, Canada
Tel: (780) 492-6130
E-mail: [email protected]
10